AN
Annovis Bio, Inc.
ANVS · NYSE
$1.16 +5.45% (+$0.06)
1M -37.36%
Market Cap $46.6M
P/E Ratio -
Div. Yield -
ROE 685.96%
Bulios Fair Price
$0.6
48.3% downside
Current Price
$1.16
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ANVS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
-
N/A P/E N/A
EV/FFO N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 15.89%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 315.92%
Asset turnover 0.00x
ROE 685.96%
Debt
43 /100
Moderate Current ratio 2.95x
Int. coverage -30.88x
Debt/Equity N/A
Stability
22 /100
Unstable Beta 1.24x
Profitable years 0
EPS volatility 18,567.30%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ANVS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Maria L. Maccecchini
Employees
7
Headquarters
Malvern
Upcoming events
11 NOV
Earnings
Upcoming earnings report